In addition, the loss of HER2 positivity occurs after treatment with trastuzumab in approximately one-third of patients with HER2-positive advanced GC; this may be the mechanism promoting resistance to subsequent anti-HER2 therapy [48,49]. The gene discussed is ERBB2; the disease is gastric cancer.